Soluble adhesion molecules in the pathogenesis of rheumatoid arthritis

Current Pharmaceutical Design

Volumn 11, Issue 5, 2005, Pages 633-653

  Volin, Michael V ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Adhesion molecules; Rheumatoid arthritis; Soluble adhesion molecules; Synovial fluid; Therapy

Indexed keywords

ADALIMUMAB; ALICAFORSEN; ANTIRHEUMATIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AURANOFIN; AUROTHIOMALATE; BUCILLAMINE; CADHERIN; CD31 ANTIGEN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FUCOIDIN; HERMES ANTIGEN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERCELLULAR ADHESION MOLECULE 3; ISIS 3082; L SELECTIN; LEFLUNOMIDE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; PADGEM PROTEIN; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE; UNINDEXED DRUG; VASCULAR ADHESION PROTEIN 1; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; CELL ADHESION; CELL TYPE; CLINICAL TRIAL; DRUG MECHANISM; FIBROBLAST; GENE EXPRESSION; HUMAN; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE HOMING; MEMORY CELL; MOLECULAR MECHANICS; NATURAL KILLER CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RNA SPLICING; T LYMPHOCYTE ACTIVATION; THROMBOCYTE ACTIVATION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELL ADHESION MOLECULES; HUMANS; SOLUBILITY; SYNOVIAL FLUID;

EID: 14044265665     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053381972     Document Type: Review

References (196)

1. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum 1996; 39: 1781-90.
2. Harris ED, Jr. Rheumatoid arthritis. Curr Opin Rheumatol 1994; 6: 287-9.
3. Muller WA. Migration of Leukocytes Across the Vascular Intima. Trends Cardiovasc Med 1995; 5: 15-20.
4. Szekanecz Z, Koch AE. Cell-cell interactions in synovitis: Endothelial cells and immune cell migration. Arthritis Res 2000; 2: 368-73.
5. Hoffmann JC, Rauker HJ, Kruger H, Bayer B, Zeidler H. Decreased levels of a soluble form of the human adhesion receptor CD58 (LFA-3) in sera and synovial fluids of patients with rheumatoid arthritis. Clin Exp Rheumatol 1996; 14: 23-9.
6. Paradies NE, Grunwald GB. Purification and characterization of NCAD90, a soluble endogenous form of N-cadherin, which is generated by proteolysis during retinal development and retains adhesive and neurite-promoting function. J Neurosci Res 1993; 36: 33-45.
7. Daniel Y, Geva E, Amit A, Eshed-Englender T, Bar-Am A, Lessing JB. Soluble endothelial and platelet selectins in serum and ascitic fluid of women with ovarian hyperstimulation syndrome. Am J Reprod Immunol 2001; 45: 154-60.
8. Baraczka K, Nekam K, Pozsonyi T, Jakab L, Szongoth M, Sesztak M. Concentration of soluble adhesion molecules (sVCAM-1, sICAM-1 and sL-selectin) in the cerebrospinal fluid and serum of patients with multiple sclerosis and systemic lupus erythematosus with central nervous involvement. Neuroimmunomodulation 2001; 9: 49-54.
9. Soriano SG, Cowan DB, Proctor MR, Scott RM. Levels of soluble adhesion molecules are elevated in the cerebrospinal fluid of children with moyamoya syndrome. Neurosurgery 2002; 50: 544-9.
10. Hoffmann JC, Dengler TJ, Knolle PA, Albert-Wolf M, Roux M, Wallich R, et al. A soluble form of the adhesion receptor CD58 (LFA-3) is present in human body fluids. Eur J Immunol 1993; 23: 3003-10.
11. Hoffmann JC, Kruger H, Luhrs J, Hamm H. Detection of soluble adhesion molecules in pleural effusions. Chest 1996; 110: 107-13.
12. Aoki S, Imai K, Yachi A. Soluble intercellular adhesion molecule- 1 (ICAM-1) antigen in patients with rheumatoid arthritis. Scand J Immunol 1993; 38: 485-90.
13. D'Auria L, Pietravalle M, Cordiali-Fei P, Ameglio F. Increased tryptase and myeloperoxidase levels in blister fluids of patients with bullous pemphigoid: correlations with cytokines, adhesion molecules and anti-basement membrane zone antibodies. Exp Dermatol 2000; 9: 131-7.
14. Agouridakis P, Kyriakou D, Alexandrakis MG, Prekates A, Perisinakis K, Karkavitsas N, et al. The predictive role of serum and bronchoalveolar lavage cytokines and adhesion molecules for acute respiratory distress syndrome development and outcome. Respir Res 2002; 3: 25.
15. Arribas J, Coodly L, Vollmer P. Kishimoto TK, Rose-John S, Massague J. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 1996; 271: 11376-82.
16. Bazil V. Physiological enzymatic cleavage of leukocyte membrane molecules. Immunol Today 1995; 16: 135-40.
17. Nitto T, Araki Y, Takeda Y, Sendo F. Pharmacological analysis for mechanisms of GPI-80 release from tumour necrosis factor-alpha-stimulated human neutrophils. Br J Pharmacol 2002; 137: 353-60.
18. Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme TM, et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro Immunology 1992; 77: 543-9.
19. Wallich R, Brenner C, Brand Y, Roux M, Reister M, Meuer S. Gene structure, promoter characterization, and basis for alternative mRNA splicing of the human CD58 gene. J Immunol 1998; 160: 2862-71.
20. Albert-Wolf M, Meuer SC, Wallich R. Immunomodulatory properties of soluble recombinant human CD58 (LFA-3) molecules. Dev Biol Stand 1992; 77: 87-92.
21. Kagi MK, Joller-Jemelka H, Wuthrich B. Soluble E-selectin correlates with disease activity in cyclosporin A-treated patients with atopic dermatitis. Allergy 1999; 54: 57-63.
22. Ghaisas NK, Shahi CN, Foley B, Goggins M, Crean P, Kelly A, et al. Elevated levels of circulating soluble adhesion molecules in peripheral blood of patients with unstable angina. Am J Cardiol 1997; 80: 617-9.
23. Mulvihill NT, Foley JB, Murphy R, Crean P, Walsh M. Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 2000; 36: 1210-6.
24. Mulvihill NT, Foley JB, Murphy RT, Curtin R, Crean PA, Walsh M. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart 2001; 85: 623-7.
25. Seidelin JB, Nielsen OH, Strom J. Soluble L-selectin levels predict survival in sepsis. Intensive Care Med 2002; 28: 1613-8.
26. Tesarova P, Kvasnicka J, Umlaufova A, Homolkova J, Kalousova M, Tesar V. Soluble adhesion molecules in female patients with breast carcinoma. Cas Lek Cesk 2003; 142: 292-9.
27. Schadendorf D, Diehl S, Zuberbier T, Schadendorf C, Henz BM. Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology 1996; 192: 89-93.
28. Skoumal M, Kolarz G, Haberhauer G, Feyertag J, Wottawa A. Is soluble CD44 variant isoform 5 useful as a predicting factor and a parameter for long term observation in rheumatoid arthritis? Ann Rheum Dis 2002; 61: 1036-7.
29. Kittl EM, Haberhauer G, Ruckser R, Selleny S, Rech-Weichselbraun I, Hinterberger W, et al. Serum levels of soluble CD44 variant isoforms are elevated in rheumatoid arthritis. Rheumatol Int 1997; 16: 181-6.
30. Haberhauer G, Kittl EM, Skoumal M, Hubl W, Wagner E, Bayer PM, et al. Increased serum levels of soluble CD44-isoform v5 in rheumatic diseases are restricted to seropositive rheumatoid arthritis. Acta Med Austriaca 1997; 24: 23-5.
31. Egerer K, Hertzer J, Feist E, Albrecht A, Rudolph PE, Domer T, et al. sE-selectin for stratifying outcome in rheumatoid arthritis. Arthritis Rheum 2003; 49: 546-8.
32. McEver RP, Moore KL, Cummings RD. Leukocyte trafficking mediated by selectin-carbohydrate interactions. J Biol Chem 1995; 270: 11025-8.
33. Patel KD, Zimmerman GA, Prescott SM, McEver RP, McIntyre TM. Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophil. J Cell Biol 1991; 112: 749-59.
34. Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PJ. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem 1989; 264: 7768-71.
35. Geng JG, Bevilacqua MP, Moore KL, McIntyre TM, Prescott SM, Kim JM, et al. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature 1990; 343: 757-60.
36. Humbria A, Diaz-Gonzalez F, Campanero MR, Arroyo AG, Laffon A, Gonzalez-Amaro R, et al. Expression of L-selectin, CD43, and CD44 in synovial fluid neutrophils from patients with inflammatory joint diseases: evidence for a soluble forms of L-selectin in synovial fluid. Arthritis Rheum 1994; 37: 342-8.
37. Fijnheer R, Frijns CJ, Korteweg J, Rommes H, Peters JH, Sixma JJ, et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997; 77: 1081-5.
38. Semenov AV, Romanov YA, Loktionova SA, Tikhomirov OY, Khachikian MV, Vasil'ev SA, et al. Production of soluble P-selectin by platelets and endothelial cells. Biochemistry (Mosc) 1999; 64: 1326-35.
39. McEver RP. Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. Blood Cells 1990; 16: 73-80.
40. Ishiwata N, Takio K, Katayama M, Watanabe K, Titani K, Ikeda Y, et al. Alternatively spliced isoform of P-selectin is present in vivo as a soluble molecule. J Biol Chem 1994; 269: 23708-15.
41. Johnston GI, Bliss GA, Newman PJ, McEver RP. Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes. J Biol Chem 1990; 265: 21381-5.
42. Berger G, Hartwell DW, Wagner DD. P-Selectin and platelet clearance. Blood 1998; 92: 4446-52.
43. Dunlop LC, Skinner MP, Bendall LJ, Favaloro EJ, Castaldi PA, Gorman JJ, et al. Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J Exp Med 1992; 175: 1147-50.
44. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA, Jr. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987; 84: 9238-42.
45. Pober JS, Bevilacqua MP, Mendrick DL, Lapierre LA, Fiers W, Gimbrone MA, Jr. Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol 1986; 136: 1680-7.
46. Newman W, Beall LD, Carson CW, Hunder GG, Graben N, Randhawa ZI, et al. Soluble e-selectin is found in supernatants of activated endothelial cells and is activated in the serum of patients with septic shock. J Immunol 1993; 150: 644-54.
47. Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584-9.
48. Lo SK, Lee S, Ramos RA, Lobb R, Rosa M, Chi-Rosso G, et al. Endothelial-leukocyte adhesion molecule 1 stimulates the adhesive activity of leukocyte integrin CR3 (CD11b/CD18, Mac-1, alpha m beta 2) on human neutrophils. J Exp Med 1991; 173: 1493-500.
49. Kumar P, Hosaka S, Koch AE. Soluble E-selectin induces monocyte chemotaxis through Src family tyrosine kinases. J Biol Chem 2001; 276: 21039-45.
50. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. A novel function for the soluble forms of adhesion molecules E-selectin and vascular cell adhesion molecule-1 as mediators of angiogenesis. J Invest Med 1995; 43: 307A.
51. Camerini D, James SP, Stamenkovic I, Seed B. Leu-8/TQ1 is the human equivalent of the Mel-14 lymph node homing receptor. Nature 1989; 342: 78-82.
52. Palecanda A, Walcheck B, Bishop DK, Jutila MA. Rapid activation-independent shedding of leukocyte L-selectin induced by cross-linking of the surface antigen. Eur J Immunol 1992; 22: 1279-86.
53. Jung TM, Dailey MO. Rapid modulation of homing receptors (gp90MEL-14) induced by activators of protein kinase C. Receptor shedding due to accelerated proteolytic cleavage at the cell surface. J Immunol 1990; 144: 3130-6.
54. Kahn J, Ingraham RH, Shirley F, Migaki GI, Kishimoto TK. Membrane proximal cleavage of L-selectin: identification of the cleavage site and a 6-kD transmembrane peptide fragment of L-selectin. J Cell Biol 1994; 125: 461-70.
55. Preece G, Murphy G, Ager A. Metalloproteinase-mediated regulation of L-selectin levels on leucocytes. J Biol Chem 1996; 271: 11634-40.
56. Walcheck B, Alexander SR, St Hill CA, Matala E. ADAM-17-independent shedding of L-selectin. J Leukoc Biol 2003; 74: 389-94.
57. Jasuja RR, Mier JW. Differential effects of hydroxamate inhibitors on PMA and ligand-induced L-Selectin down-modulation: role of membrane proximal and cytoplasmic domains. Int J Immunopathol Pharmacol 2000; 13: 1-12.
58. Gomez-Gaviro MV, Gonzalez-Alvaro I, Dominguez-Jimenez C, Peschon J, Black RA, Sanchez-Madrid F, et al. Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs. J Biol Chem 2002; 277: 38212-21.
59. Strausbaugh HJ, Rosen SD. A potential role for annexin 1 as a physiologic mediator of glucocorticoid-induced L-selectin shedding from myeloid cells. J Immunol 2001; 166: 6294-300.
60. Schleiffenbaum B, Spertini O, Tedder TF. Soluble L-selectin is present in human plasma at high levels and retains functional activity. J Cell Biol 1992; 119: 229-38.
61. Tu L, Poe JC, Kadono T, Venturi GM, Bullard DC, Tedder TF, et al. A functional role for circulating mouse L-selectin in regulating leukocyte/endothelial cell interactions in vivo. J Immunol 2002; 169: 2034-43.
62. Ager A. Regulation of lymphocyte migration into lymph nodes by high endothelial venules. Biochem Soc Trans 1997; 25: 421-8.
63. Holness CL, Simmons DL. Structural motifs for recognition and adhesion in members of the immunoglobulin superfamily. J Cell Sci 1994; 107: 2065-70.
64. Hope SA, Meredith IT. Cellular adhesion molecules and cardiovascular disease. Part I. Their expression and role in atherogenesis. Intern Med J 2003; 33: 380-6.
65. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM- 1). J Immunol 1986; 137: 245-54.
66. Robledo O, Papaioannou A, Ochietti B, Beauchemin C, Legault D, Cantin A, et al. ICAM-1 isoforms: specific activity and sensitivity to cleavage by leukocyte elastase and cathepsin G. Eur J Immunol 2003; 33: 1351-60.
67. Wakatsuki T, Kimura K, Kimura F, Shinomiya N, Ohtsubo M, Ishizawa M, et al. A distinct mRNA encoding a soluble form of ICAM-1 molecule expressed in human tissues. Cell Adhes Commun 1995; 3: 283-92.
68. Giorelli M, De Blasi A, Defazio G, Avolio C, Iacovelli L, Livrea P, et al. Differential regulation of membrane bound and soluble ICAM 1 in human endothelium and blood mononuclear cells: effects of interferon beta-1a. Cell Commun Adhes 2002; 9: 259-72.
69. Cybulsky MI, Fries JW, Williams AJ, Sultan P, Davis VM, Gimbrone MA Jr, et al. Alternative splicing of human VCAM-1 in activated vascular endothelium. Am J Pathol 1991; 138: 815-20.
70. Damle NK, Klussman K, Leytze G, Ochs HD, Aruffo A, Linsley PS, et al. Costimulation via vascular cell adhesion molecule-1 induces in T cells increased responsiveness to the CD28 counter-receptor B7. Cell Immunol 1993; 148: 144-56.
71. Burkly LC, Jakubowski A, Newman BM, Rosa MD, Chi-Rosso G, Lobb RR. Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T cell proliferation. Eur J Immunol 1991; 21: 2871-5.
72. Wellicome SM, Kapahi P, Mason JC, Lebranchu Y, Yarwood H, Haskard DO. Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1993; 92: 412-8.
73. Garton KJ, Gough PJ, Philalay J, Wille PT, Blobel CP, Whitehead RH, et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem 2003; 278: 37459-64.
74. Terry RW, Kwee L, Levine JF, Labow MA. Cytokine induction of an alternatively spliced murine vascular cell adhesion molecule (VCAM) mRNA encoding a glycosylphosphatidylinositol-anchored VCAM protein. Proc Natl Acad Sci USA 1993; 90: 5919-23.
75. Pirozzi G, Terry RW, Labow MA. Murine vascular cell adhesion molecule-1 (VCAM-1) proteins encoded by alternatively spliced mRNAs are differentially targeted in polarized cells. Cell Adhes Commun 1994; 2: 549-56.
76. Kitani A, Nakashima N, Izumihara T, Inagaki M, Baoui X, Yu S, et al. Soluble VCAM-1 induces chemotaxis of jurkat and synovial fluid T-cells bearing high affinity very late antigen-4. J Immunol 1998; 161: 4931-8.
77. Tokuhira M, Hosaka S, Volin MV, Haines GK3, Katschke KJ Jr, Kim S, et al. Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritis Rheum 2000; 43: 1122-33.
78. Koch AE, Halloran MM, Haskell CJ, Shah MR; Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995; 376: 517-9.
79. Woska JR Jr, Morelock MM, Jeanfavre DD, Caviness GO, Bormann BJ, Rothlein R. Molecular comparison of soluble intercellular adhesion molecule (sICAM)-1 and sICAM-3 binding to lymphocyte function-associated antigen-1. J Biol Chem 1998; 273: 4725-33.
80. Verkarre V, Patey-Mariaud dS, Vazeux R, Teillac-Hamel D, Chretien-Marquet B, Le Bihan C, et al. ICAM-3 and E-selectin endothelial cell expression differentiate two phases of angiogenesis in infantile hemangiomas. J Cutan Pathol 1999; 26: 17-24.
81. Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000; 100: 575-85.
82. Binnerts ME, van Kooyk Y, Simmons DL, Figdor CG. Distinct binding of T lymphocytes to ICAM- 1, -2 or -3 upon activation of LFA-1. Eur J Immunol 1994; 24: 2155-60.
83. Feldhaus MJ, Kessel JM, Zimmerman GA, McIntyre TM. Engagement of ICAM-3 activates polymorphonuclear leukocytes: aggregation without degranulation or beta 2 integrin recruitment. J Immunol 1998; 161: 6280-7.
84. del Pozo MA, Pulido R, Munoz C, Alvarez V, Humbria A, Campanero MR, et al. Regulation of ICAM-3 (CD50) membrane expression on human neutrophils through a proteolytic shedding mechanism. Eur J Immunol 1994; 24: 2586-94.
85. Newman PJ. The biology of PECAM-1. J Clin Invest 1997; 99: 3-8.
86. Piali L, Hammel P, Uherek C, Bachmann F, Gisler RH, Dunon D, et al. CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol 1995; 130: 451-60.
87. Zocchi MR, Ferrero E, Leone BE, Rovere P, Bianchi E, Toninelli E, et al. CD31/PECAM-1-driven chemokine-independent transmigration of human T lymphocytes. Eur J Immunol 1996; 26: 759-67.
88. Bogen SA, Baldwin HS, Watkins SC, Albelda SM, Abbas AK. Association of murine CD31 with transmigrating lymphocytes following antigenic stimulation. Am J Pathol 1992; 141: 843-54.
89. Scalia R, Lefer AM. In vivo regulation of PECAM-1 activity during acute endothelial dysfunction in the rat mesenteric microvasculature. J Leukoc Biol 1998; 64: 163-9.
90. Liao F, Huynh HK, Eiroa A, Greene T, Polizzi E, Muller WA. Migration of monocytes across endothelium and passage through extracellular matrix involve separate molecular domains of PECAM-1. J Exp Med 1995; 182: 1337-43.
91. Christofidou-Solomidou M, Nakada MT, Williams J, Muller WA, DeLisser HM. Neutrophil platelet endothelial cell adhesion molecule-1 participates in neutrophil recruitment at inflammatory sites and is down-regulated after leukocyte extravasation. J Immunol 1997; 158: 4872-8.
92. Kim CS, Wang T, Madri JA. Platelet endothelial cell adhesion molecule-1 expression modulates endothelial cell migration in vitro Lab Invest 1998; 78: 583-90.
93. DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, et al. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 1997; 151: 671-7.
94. Goldberger A, Middleton KA, Oliver JA, Paddock C, Yan HC, DeLisser HM, et al. Biosynthesis and processing of the cell adhesion molecule PECAM-1 includes production of a soluble form. J Biol Chem 1994; 269: 17183-91.
95. Krensky AM, Sanchez-Madrid F, Robbins E, Nagy JA, Springer TA, Burakoff SJ. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. J Immunol 1983; 131: 611-6.
96. Seed B. An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2. Nature 1987; 329: 840-2.
97. Dustin ML, Selvaraj P, Mattaliano RJ, Springer TA. Anchoring mechanisms for LFA-3 cell adhesion glycoprotein at membrane surface. Nature 1987; 329: 846-8.
98. Wallner BP, Frey AZ, Tizard R, Mattaliano RJ, Hession C, Sanders ME, et al. Primary structure of lymphocyte function-associated antigen 3 (LFA-3). The ligand of the T lymphocyte CD2 glycoprotein. J Exp Med 1987; 166: 923-32.
99. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol 1999; 52: 189-96.
100. Endo K, Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic, parameters, p53 expression, and patient survival. J Hepatol 2000; 32: 78-84.
101. DeGrendele HC, Estess P, Picker LJ, Siegelman MH. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway. J Exp Med 1996; 183: 1119-30.
102. Brennan FR, Mikecz K, Glant TT, Jobanputra P, Pinder S, Bavington C, et al. CD44 expression by leucocytes in rheumatoid arthritis and modulation by specific antibody: implications for lymphocyte adhesion to endothelial cells and synoviocytes in vitro. Scand J Immunol 1997; 45: 213-20.
103. Hale LP, Singer KH, Haynes BF. CD44 antibody against In(Lu)-related p80, lymphocyte-homing receptor molecule inhibits the binding of human erythrocytes to T cells. J Immunol 1989; 143: 3944-8.
104. Yu Q, Toole BP. A new alternatively spliced exon between v9 and v10 provides a molecular basis for synthesis of soluble CD44. J Biol Chem 1996; 271: 20603-7.
105. Smith DJ, Salmi M, Bono P, Hellman J, Leu T, Jalkanen S. Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule. J Exp Med 1998; 188: 17-27.
106. Salmi M, Jalkanen S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science 1992; 257: 1407-9.
107. Jaakkola K, Nikula T, Holopainen R, Vahasilta T, Matikainen MT, Laukkanen ML, et al. In vivo detection of vascular adhesion protein-1 in experimental inflammation. Am J Pathol 2000; 157: 463-71.
108. Salmi M, Kalimo K, Jalkanen S. Induction and function of vascular adhesion protein-1 at sites of inflammation. J Exp Med 1993; 178: 2255-60.
109. Kurkijarvi R, Adams DH, Leino R, Mottonen T, Jalkanen S, Salmi M. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases. J Immunol 1998; 161: 1549-57.
110. Ohtake K, Takei H, Watanabe T, Sato Y, Yamashita T, Sudo K, et al. A monoclonal antibody modulates neutrophil adherence while enhancing cell motility. Microbiol Immunol 1997; 41: 67-72.
111. Suzuki K, Watanabe T, Sakurai S, Ohtake K, Kinoshita T, Araki A, et al. A novel glycosylphosphatidyl inositol-anchored protein on human leukocytes: a possible role for regulation of neutrophil adherence and migration. J Immunol 1999; 162: 4277-84.
112. Takeda Y, Fu J, Suzuki K, Sendo D, Nitto T, Sendo F, et al. Expression of GPI-80, a beta2-integrin-associated glycosylphosphatidylinositol-anchored protein, requires neutrophil differentiation with dimethyl sulfoxide in HL-60 cells. Exp Cell Res 2003; 286: 199-208.
113. Koike S, Takeda Y, Hozumi Y, Okazaki S, Aoyagi M, Sendo F. Immunohistochemical localization in human tissues of GPI-80, a novel glycosylphosphatidyl inositol-anchored protein that may regulate neutrophil extravasation. Cell Tissue Res 2002; 307: 91-9.
114. Sendo D, Takeda Y, Ishikawa H, Sendo F, Araki Y. Localization of GPI-80, a beta2-integrin-associated glycosylphosphatidyl-inositol anchored protein, on strongly CD14-positive human monocytes. Immunobiology 2003; 207: 217-21.
115. Dahlgren C, Karlsson A, Sendo, F. Neutrophil secretory vesicles are the intracellular reservoir for GPI-80, a protein with adhesion-regulating potential. J Leukoc Biol 2001; 69: 57-62.
116. Nakamura-Sato Y, Sasaki K, Watanabe H, Araki Y, Sendo F. Clustering on the forward surfaces of migrating neutrophils of a novel GPI-anchored protein that may regulate neutrophil adherence and migration. J Leukoc Biol 2000; 68: 650-4.
117. Huang J, Takeda Y, Watanabe T, Sendo F. A sandwich ELISA for detection of soluble GPI-80, a glycosylphosphatidyl-inositol (GPI)-anchored protein on human leukocytes involved in regulation of neutrophil adherence and migration - its release from activated neutrophils and presence in synovial fluid of rheumatoid arthritis patients. Microbiol Immunol 2001; 45: 467-71.
118. Takeda I, Kaise S, Nishimaki T, Kasukawa R. Soluble P-selectin in the plasma of patients with connective tissue diseases. Int Arch Allergy Immunol 1994; 105: 128-34.
119. Littler AJ, Buckley CD, Wordsworth P, Collins I, Martinson J, Simmons DL. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br J Rheumatol 1997; 36: 164-9.
120. Nassonov EL, Samsonov MY, Chichasova NV, Nikiphorova EL, Tilz GP, Demel U, et al. Soluble adhesion molecules in rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 808-10.
121. Amin HM, Ahmad S, Walenga JM, Hoppensteadt DA, Leitz H, Fareed J. Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders. Clin Appl Thromb Hemost 2000; 6: 71-6.
122. Hosaka S, Shah MR, Pope RM, Koch AE. Soluble forms of P-selectin and intercellular adhesion molecule-3 in synovial fluids. Clin Immunol Immunopathol 1996; 78: 276-82.
123. Tak PP, Thurkow EW, Daha MR, Kluin PM, Smeets TJ, Meinders AE, et al. Expression of adhesion molecules in early rheumatoid synovial tissue. Clin Immunol Immunopathol 1995; 77: 236-42.
124. Veale DJ, Maple C, Kirk G, McLaren M, Belch JJ. Soluble cell adhesion molecules - P-selectin and ICAM-1, and disease activity in patients receiving sulphasalazine for active rheumatoid arthritis. Scand J Rheumatol 1998; 27: 296-9.
125. Kriegsmann J, Keyszer GM, Geiler T, Lagoo AS, Lagoo-Deenadayalan S, Gay RE, et al. Expression of E-selectin messenger RNA and protein in rheumatoid arthritis. Arthritis Rheum 1995; 38: 750-4.
126. To SS, Newman PM, Hyland VJ, Robinson BG, Schrieber L. Regulation of adhesion molecule expression by human synovial microvascular endothelial cells in vitro. Arthritis Rheum 1996; 39: 467-77.
127. Koch AE, Turkiewicz W, Harlow LA, Pope RM. Soluble E-selectin in arthritis. Clin Immunol Immunopathol 1993; 69: 29-35.
128. Carson CW, Beall LD, Hunder GG, Johnson CM, Newman W. Soluble e-selectin is increased in inflammatory synovial fluid. J Rheumatol 1994; 21: 605-11.
129. Blann AD, Herrick A, Jayson MI. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol 1995; 34: 814-9.
130. Salih AM, Nixon NB, Dawes PT, Mattey DL. Soluble adhesion molecules and anti-endothelial cell antibodies in patients with rheumatoid arthritis complicated by peripheral neuropathy. J Rheumatol 1999; 26: 551-5.
131. El M, Ashour S, Moustafa H, Ahmed I. Altered levels of soluble adhesion molecules in patients with rheumatoid arthritis complicated by peripheral neuropathy. J Rheumatol 2002; 29: 57-61.
132. Sfikakis PP, Charalambopoulos D, Vaiopoulos G, Mavrikakis M. Circulating P- and L-selectin and T-lymphocyte activation and patients with autoimmune rheumatic diseases. Clin Rheumatol 1999; 18: 28-32.
133. Bond A, Hay FC. L-selectin expression on the surface of peripheral blood leucocytes from rheumatoid arthritis patients is linked to disease activity. Scand J Immunol 1997; 46: 312-6.
134. Honig M, Peter HH, Jantscheff P, Grunert F. Synovial PMN show a coordinated up-regulation of CD66 molecules. J Leukoc Biol 1999; 66: 429-36.
135. Koch AE, Shah MR, Harlow LA, Lovis RM, Pope RM. Soluble intercellular adhesion molecule-1 in arthritis. Clin Immunol Immunopathol 1994; 71: 208-15.
136. Cush JJ, Rothlein R, Lindsley HB, Mainolfi EA, Lipsky PE. Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum 1993; 36: 1098-102.
137. Mason JC, Kapahi P, Haskard DO. Detection of increased levels of circulating intercellular adhesion molecule 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus. Arthritis Rheum 1993; 36: 519-27.
138. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, et al. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 2002; 61: 804-9.
139. Machold KP, Kiener HP, Graninger W, Franinger WB. Soluble intercellular adhesion molecule-1 (sICAM-1) in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 1993; 68: 74-8.
140. den Broeder AA, Joosten LA, Saxne T, Heinegard D, Fenner H, Miltenburg AM, et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002; 61: 311-8.
141. Shingu M, Hashimoto M, Nobunaga M, Isayama T, Yasutake C, Naono T. Production of soluble ICAM-1 by mononuclear cells from patients with rheumatoid arthritis patients. Inflammation 1994; 18: 23-34.
142. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maim RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 1996; 39: 1082-91.
143. Koch AE, Burrows JC, Haines GK, Carlos TM, Harlan JM, Leibovich SJ. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab Invest 1991; 64: 313-20.
144. Furuzawa-Carballeda J, Alcocer-Varela J. Interleukin-8, interleukin-10, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression levels are higher in synovial tissue from patients with rheumatoid arthritis than in osteoarthritis. Scand J Immunol 1999; 50: 215-22.
145. Kolopp-Sarda MN, Guillemin F, Chary-Valckenaere I, Bene MC, Pourel J, Faure GC. Longitudinal study of rheumatoid arthritis patients discloses sustained elevated serum levels of soluble CD106 (V-CAM). Clin Exp Rheumatol 2001; 19: 165-70.
146. Mulherin DM, Veale DJ, Belch JJ, Bresnihan B, Fitzgerald O. Adhesion molecules in untreated inflammatory arthritis: synovial expression and levels in synovial fluid and serum. QJM 1996; 89: 195-203.
147. Voskuyl AE, Martin S, Melchers L, Zwinderman AH, Weichselbraun I, Breedveld FC. Levels of circulating intercellular adhesion molecule-1 and -3 but not circulating endothelial leucocyte adhesion molecule are increased in patients with rheumatoid vasculitis. Br J Rheumatol 1995; 34: 311-5.
148. Martin S, Peter R, Melchers I, Wagner R, Bertrams J, Voskuyl AE, et al. Circulating forms of ICAM-3 (cICAM-3): elevated levels in autoimmune diseases and lack of association with cICAM-1. J Immunol 1995; 154: 1951-5.
149. Szekanecz Z, Haines GK, Lin TR, Harlow LA, Goerdt S, Rayan G, et al. Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum 1994; 37: 221-31.
150. El-Gabalawy H, Gallatin M, Vazeux R, Peterman G, Wilkins J. Expression of ICAM-R (ICAM-3), novel counter-receptor for LFA-1, in rheumatoid and nonrheumatoid synovium: comparison with other adhesion molecules. Arthritis Rheum 1994; 37: 846-54.
151. Volin MV, Szekanecz Z, Halloran MM, Woods JM, Magua J, Damergis JA Jr, et al. PECAM-1 and leukosialin (CD43) expression correlate with heightened inflammation in rat adjuvant-induced arthritis. Exp Mol Pathol 1999; 66: 211-9.
152. Johnson BA, Haines GK, Harlow LA, Koch AE. Adhesion molecule expression in human synovial tissue. Arthritis Rheum 1993; 36: 137-46.
153. Szekanecz Z, Haines GK, Harlow LA, Shah MR, Fong TW, Fu R, et al. Increased expression of the synovial adhesion molecules CD66a, CD66b and CD31 in rheumatoid arthritis. Clin Immunol Immunopathol 1995; 76: 180-6.
154. Felzmann T, Gadd S, Majdic O, Maurer D, Petera P, Smolen J, et al. Analysis of function-associated receptor molecules on peripheral blood and synovial fluid granulocytes from patients with rheumatoid and reactive arthritis. J Clin Immunol 1991; 11: 205-12.
155. Gadd SJ, Felzmann T, Majdic O, Maurer D, Petera P, Chen WJ, et al. Phenotypic analysis of functionally associated molecules on peripheral blood and synovial fluid monocytes from arthritis patients. Rheumatol Int 1992; 12: 153-7.
156. Hale LP, Martin ME, McCollum DE, Nunley JA, Springer TA, Singer KH, et al. Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment. Arthritis Rheum 1989; 32: 22-30.
157. Takahashi H, Soderstrom K, Nilsson E, Kiessling R, Patarroyo M. Integrins and other adhesion molecules on lymphocytes from synovial fluid and peripheral blood of rheumatoid arthritis patients. Eur J Immunol 1992; 22: 2879-85.
158. Haynes BF, Hale LP, Patton KL, Martin ME, McCallum RM. Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthritis Rheum 1991; 34: 1434-43.
159. Fujii K, Tanaka Y, Hubscher S, Saito K, Ota T, Eto S. Cross-linking of CD44 on rheumatoid synovial cells up-regulates VCAM-1. J Immunol 1999; 162: 2391-8.
160. Kelleher D, Murphy A, Hall N, Omary MB, Kearns G, Long A, et al. Expression of CD44 on rheumatoid synovial fluid lymphocytes. Ann Rheum Dis 1995; 54: 566-70.
161. Nedvetzki S, Golan I, Assayag N, Gonen E, Caspi D, Gladnikoff M, et al. A mutation in a CD44 variant of inflammatory cells enhances the mitogenic interaction of FGF with its receptor. J Clin Invest 2003; 111: 1211-20.
162. Mikecz K, Dennis K, Shi M, Kim JH. Modulation of hyaluronan receptor (CD44) function in vivo in a murine model of rheumatoid arthritis. Arthritis Rheum 1999; 42: 659-68.
163. Salmi M, Rajala P, Jalkanen S. Homing of mucosal leukocytes to joints: distinct endothelial ligands in synovium mediate leukocyte-subtype specific adhesion. J Clin Invest 1997; 99: 2165-72.
164. Akin E, Aversa J, Steere AC. Expression of adhesion molecules in synovia of patients with treatment-resistant lyme arthritis. Infect Immun 2001; 69: 1774-80.
165. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46: 328-46.
166. Kikuchi H, Isshi K, Hirohata S. Inhibitory effects of bucillamine on the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. Int Immunopharmacol 2004; 4: 119-26.
167. Hirohata S, Lipsky PE. Regulation of B cell function by bucillamine, a novel disease-modifying antirheumatic drug. Clin Immunol Immunopathol 1993; 66: 43-51.
168. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000; 59: 841-9.
169. Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenburg R, et al. Modulation of inflammation and métalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000; 43: 1820-30.
170. Cutolo M, Sulli A, Ghiorzo P, Pizzorni C, Craviotto C, Villaggio B. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 297-302.
171. Corkill MM, Kirkham BW, Haskard DO, Barbatis C, Gibson T, Panayi GS. Gold treatment of rheumatoid arthritis decreases synovial expression of the endothelial leukocyte adhesion receptor ELAM-1. J Rheumatol 1991; 18: 1453-60.
172. Newman PM, To SS, Robinson BG, Hyland VJ, Schrieber L. Effect of gold sodium thiomalate and its thiomalate component on the in vitro expression of endothelial cell adhesion molecules. J Clin Invest 1994; 94: 1864-71.
173. Liu J, Akahoshi T, Namai R, Matsui T, Kondo H. Effect of auranofin, an antirheumatic drug, on neutrophil apoptosis. Inflamm Res 2000; 49: 445-51.
174. Heimburger M, Lerner R, Palmblad J. Effects of antirheumatic drugs on adhesiveness of endothelial cells and neutrophils. Biochem Pharmacol 1998; 56: 1661-9.
175. Volin MV, Harlow LA, Woods JM, Campbell PL, Amin MA, Tokuhira M, et al. Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis. Arthritis Rheum 1999; 42: 1927-35.
176. Dolhain RJ, Tak PP, Dijkmans BA, De Kuiper P, Breedveld FC, Miltenburg AM. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol 1998; 37: 502-8.
177. Dahlman-Ghozlan K, Heilborn JD, Stephansson E. Circulating levels of soluble E-selectin, ICAM-1 and VCAM-1 in bullous pemphigoid during low-dose methotrexate therapy. A prospective study. Exp Dermatol 2000; 9: 336-40.
178. Youssef PP, Triantafillou S, Parker A, Coleman M, Roberts-Thomson PJ, Ahern MJ, et al. Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis. Reduced E-selectin and intercellular adhesion molecule 1 expression. Arthritis Rheum 1996; 39: 1970-9.
179. Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1077-81.
180. Klimiuk PA, Sierakowski S, Domyslawska I, Fiedorczyk M, Chwiecko J. Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp (Warsz) 2004; 52: 36-42.
181. Ulbrich H, Eriksson EE, Lindbom L. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci 2003; 24: 640-7.
182. Walter UM, Issekutz AC. The role of E- and P-selectin in neutrophii and monocyte migration in adjuvant-induced arthritis in the rat. Eur J Immunol 1997; 27: 1498-505.
183. Issekutz AC, Mu JY, Liu G, Melrose J, Berg EL. E-selectin, but not P-selectin, is required for development of adjuvant-induced arthritis in the rat. Arthritis Rheum 2001; 44: 1428-37.
184. Jasin HE, Lightfoot E, Davis LS, Rothlein R, Faanes RB, Lipsky PE. Amelioration of antigen-induced arthritis in rabbits treated with monoclonal antibodies to leukocyte adhesion molecules. Arthritis Rheum 1992; 35: 541-9.
185. Birner U, Issekutz TB, Issekutz AC. The role of selectins in VLA-4 and CD18-independent neutrophil migration. Eur J Immunol 1999; 29: 1094-100.
186. Zeidler A, Brauer R, Thoss K, Bahnsen J, Heinrichs V, Jablonski-Westrich D, et al. Therapeutic effects of antibodies against adhesion molecules in murine collagen type II-induced arthritis. Autoimmunity 1995; 21: 245-52.
187. Kakimoto K, Nakamura T, Ishii K, Takashi T, Iigou H, Yagita H, et al. The effect of anti-adhesion molecule antibody on the development of collagen-induced arthritis. Cell Immunol 1992; 142: 326-37.
188. Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994; 37: 992-9.
189. Kavanaugh AF, Davis LS, Jain RI, Nichols LA, Norris SH, Lipsky PE. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol 1996; 23: 1338-44.
190. Kavanaugh AF, Schulze-Koops H, Davis LS, Lipsky PE. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum 1997; 40: 849-53.
191. Verdrengh M, Erlandsson-Harris H, Tarkowski A. Role of selectins in experimental Staphylococcus aureus-induced arthritis. Eur J Immunol 2000; 30: 1606-13.
192. Henry SP, Templin MV, Gillett N, Rojko J, Levin AA. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Toxicol Pathol 1999; 27: 95-100.
193. Maksymowych WP, Blackburn WD Jr, Tami JA, Shanahan WR, Jr. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis. J Rheumatol 2002; 29: 447-53.
194. Saeki T, Naya A. CCR1 chemokine receptor antagonist. Curr Pharm Design 2003; 9(15): 1201-8.
195. Trial J, Rice L. Erythropoietin withdrawal leads to the destruction of young red cells at the endothelial-macrophage interface. Curr Pharm Design 2004; 10(2): 183-90.
196. Turesson C. Endothelial expression of MHC class II molecules in autoimmune disease. Curr Pharm Design 2004; 10(2): 129-43.